Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum

Current Opinion in Infectious Diseases

Volumn 24, Issue 6, 2011, Pages 570-577

  O'Brien, Connor ^a   Henrich, Philipp P ^a   Passi, Neha ^a   Fidock, David A ^a,b  

^a Department of Medicine   (United States)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; ARTEMISININ; ARTESUNATE; ARTESUNATE PLUS MEFLOQUINE; BENFLUMETOL; MEFLOQUINE;

GENE AMPLIFICATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALARIA FALCIPARUM; META ANALYSIS (TOPIC); PARASITE CLEARANCE; PARASITEMIA; PLASMODIUM FALCIPARUM; REVIEW; SOUTHEAST ASIA;

ANTIMALARIALS; ARTEMISININS; ASIA, SOUTHEASTERN; DRUG RESISTANCE; HUMANS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM;

EID: 80054973132     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32834cd3ed     Document Type: Review

References (73)

1. World Health Organization. WHO global report on antimalarial drug efficacy and drug resistance: 2000-2010. Geneva, Switzerland: WHO Press. http://www.who.int/malaria/publications/atoz/9789241500470/en/index.html [accessed 1 August 2010].
2. Snow RW, Trape JF, Marsh K. The past, present and future of childhood malaria mortality in Africa. Trends Parasitol 2001; 17:593-597. (Pubitemid 34088120)
3. Lin JT, Juliano JJ, Wongsrichanalai C. Drug-resistant malaria: the era of ACT. Curr Infect Dis Rep 2010; 12:165-173.
4. Crawley J, Chu C, Mtove G, Nosten F. Malaria in children. Lancet 2010; 375:1468-1481.
5. White NJ. Qinghaosu (artemisinin): the price of success. Science 2008; 320:330-334. (Pubitemid 351555649)
6. Maude RJ, Pontavornpinyo W, Saralamba S, et al. The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia. Malar J 2009; 8:31.
7. Price RN, Nosten F, Luxemburger C, et al. Effects of artemisinin derivatives on malaria transmissibility. Lancet 1996; 347:1654-1658. (Pubitemid 26177386)
8. Eastman RT, Fidock DA. Artemisinin-based combination therapies: A vital tool in efforts to eliminate malaria. Nat Rev Microbiol 2009; 7:864-874.
9. Jambou R, Le Bras J, Randrianarivelojosia M. Pitfalls in new artemisinincontaining antimalarial drug development. Trends Parasitol 2011; 27:82-90.
10. Li GQ, Guo XB, Fu LC, et al. Clinical trials of artemisinin and its derivatives in the treatment of malaria in China. Trans R Soc TropMed Hyg 1994; 88 (SUPPL. 1):S5-S6.
11. Stepniewska K, Ashley E, Lee SJ, et al. In vivo parasitological measures of artemisinin susceptibility. J Infect Dis 2010; 201:570-579.
12. Wells TN, Alonso PL, Gutteridge WE. New medicines to improve control and contribute to the eradication of malaria. Nat Rev Drug Discov 2009; 8:879-891.
13. Vinetz JM, Clain J, Bounkeua V, et al. Chemotherapy of malaria. In: Brunton L, Chabner B, Knollman B, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 12th ed., New York, NY: McGraw Hill Medical; 2011. pp. 1383-1418.
14. Hastings I. How artemisinin-containing combination therapies slow the spread of antimalarial drug resistance. Trends Parasitol 2011; 27:67-72.
15. Vijaykadga S, Rojanawatsirivej C, Cholpol S, et al. In vivo sensitivity monitoring of mefloquine monotherapy and artesunate-mefloquine combinations for the treatment of uncomplicated falciparum malaria in Thailand in 2003. Trop Med Int Health 2006; 11:211-219.
16. Denis MB, Tsuyuoka R, Poravuth Y, et al. Surveillance of the efficacy of artesunate and mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health 2006; 11:1360-1366. (Pubitemid 44289723)
17. Noedl H, Se Y, Schaecher K, et al. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008; 359:2619-2620.
18. Noedl H, Se Y, Sriwichai S, et al. Artemisinin resistance in Cambodia: A clinical trial designed to address an emerging problem in Southeast Asia. Clin Infect Dis 2010; 51:e82-e89.
19. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361:455-467.
20. Htut ZW. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361:1807-1808; author reply 1808.
21. Dondorp AM, Yeung S, White L, et al. Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol 2010; 8:272-280.
22. Newton PN, Fernandez FM, Plancon A, et al. A collaborative epidemiological investigation into the criminal fake artesunate trade in South East Asia. PLoS Med 2008; 5:e32.
23. Rathod PK, McErlean T, Lee PC. Variations in frequencies of drug resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A 1997; 94:9389-9393. (Pubitemid 27357839)
24. Anderson TJ, Nair S, Nkhoma S, et al. High heritability of malaria parasite clearance rate indicates a genetic basis for artemisinin resistance in western Cambodia. J Infect Dis 2010; 201:1326-1330.
25. White NJ, Pongtavornpinyo W. The de novo selection of drug-resistant malaria parasites. Proc Biol Sci 2003; 270:545-554. (Pubitemid 36308233)
26. Enserink M. Malaria's drug miracle in danger. Science 2010; 328:844-846.
27. Wellems TE, Plowe CV. Chloroquine-resistant malaria. J Infect Dis 2001; 184:770-776. (Pubitemid 32826429)
28. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2002; 2:209-218. (Pubitemid 34464751)
29. Wootton JC, Feng X, Ferdig MT, et al. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature 2002; 418:320-323. (Pubitemid 34790681)
30. Roper C, Pearce R, Nair S, et al. Intercontinental spread of pyrimethamineresistant malaria. Science 2004; 305:1124.
31. Cui L, Yan G, Sattabongkot J, et al. Malaria in the Greater Mekong Subregion: heterogeneity and complexity. Acta Trop (in press).
32. Carrara VI, Zwang J, Ashley EA, et al. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One 2009; 4:e4551.
33. Thanh NV, Toan TQ, Cowman AF, et al. Monitoring for Plasmodium falciparum drug resistance to artemisinin and artesunate in Binh Phuoc Province, Vietnam: 1998-2009. Malar J 2010; 9:181.
34. Sibley CH, Guerin PJ, Ringwald P. Monitoring antimalarial resistance: launching a cooperative effort. Trends Parasitol 2010; 26:221-224.
35. Kachur SP, MacArthur JR, Slutsker L. A call to action: addressing the challenge of artemisinin-resistant malaria. Expert Rev Anti Infect Ther 2010; 8:365-366.
36. Picot S, Olliaro P, de Monbrison F, et al. A systematic review and metaanalysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar J 2009; 8:89.
37. Lim P, Wongsrichanalai C, Chim P, et al. Decreased in vitro susceptibility of Plasmodium falciparum isolates to artesunate, mefloquine, chloroquine, and quinine in Cambodia from 2001 to 2007. Antimicrob Agents Chemother 2010; 54:2135-2142.
38. Huttinger F, Satimai W, Wernsdorfer G, et al. Sensitivity to artemisinin, mefloquine and quinine of Plasmodium falciparum in northwestern Thailand. Wien Klin Wochenschr 2010; 122 (SUPPL. 3):52-56.
39. Ding XC, Beck HP, Raso G. Plasmodium sensitivity to artemisinins: magic bullets hit elusive targets. Trends Parasitol 2010; 27:73-81.
40. O'Neill PM, Barton VE, Ward SA. The molecular mechanism of action of artemisinin: the debate continues. Molecules 2010; 15:1705-1721.
41. Krishna S, Pulcini S, Fatih F, Staines H. Artemisinins and the biological basis for the PfATP6/SERCA hypothesis. Trends Parasitol 2011; 26:517-523.
42. Ecker A, Lehane A, Fidock DA. Molecular markers of Plasmodium resistance to antimalarials. In: Staines HM, Krishna S, editors. Treatment and prevention of malaria: antimalarial drug chemistry, action and use. Basel, Switzerland: Birkhauser Verlag (in press).
43. Raj DK, Mu J, Jiang H, et al. Disruption of a Plasmodium falciparum multidrug resistance-associated protein (PfMRP) alters its fitness and transport of antimalarial drugs and glutathione. J Biol Chem 2009; 284:7687-7696.
44. Hunt P, Martinelli A, Modrzynska K, et al. Experimental evolution, genetic analysis and genome re-sequencing reveal the mutation conferring artemisinin resistance in an isogenic lineage of malaria parasites. BMC Genomics 2010; 11:499.
45. Valderramos SG, Fidock DA. Transporters involved in resistance to antimalarial drugs. Trends Pharmacol Sci 2006; 27:594-601. (Pubitemid 44572395)
46. Klonis N, Crespo-Ortiz MP, Bottova I, et al. Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion. Proc Natl Acad Sci U S A 2011; 108:11405-11410.
47. Witkowski B, Lelievre J, Barragan MJ, et al. Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mechanism. Antimicrob Agents Chemother 2010; 54:1872-1877.
48. Teuscher F, Gatton ML, Chen N, et al. Artemisinin-induced dormancy in Plasmodium falciparum: duration, recovery rates, and implications in treatment failure. J Infect Dis 2010; 202:1362-1368.
49. Mok S, Imwong M, Mackinnon MJ, et al. Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription. BMC Genomics 2011; 12:391.
50. Goldberg DE. Hemoglobin degradation. Curr Top Microbiol Immunol 2005; 295:275-291. (Pubitemid 41236519)
51. Hartwig CL, Rosenthal AS, D'Angelo J, et al. Accumulation of artemisinin trioxane derivatives within neutral lipids of Plasmodium falciparummalaria parasites is endoperoxide-dependent. Biochem Pharmacol 2009; 77:322-336.
52. Cui L, Su XZ. Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev Anti Infect Ther 2009; 7:999-1013.
53. Valderramos SG, Scanfeld D, Uhlemann AC, et al. Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance. Antimicrob Agents Chemother 2010; 54:3842-3852.
54. Price RN, Uhlemann AC, Brockman A, et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 2004; 364:438-447. (Pubitemid 39036891)
55. Sidhu AB, Uhlemann AC, Valderramos SG, et al. Decreasing pfmdr1 copy number in Plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J Infect Dis 2006; 194:528-535. (Pubitemid 44162666)
56. Chavchich M, Gerena L, Peters J, et al. Role of pfmdr1 amplification and expression in induction of resistance to artemisinin derivatives in Plasmodium falciparum. Antimicrob Agents Chemother 2010; 54:2455-2464.
57. Chen N, Chavchich M, Peters JM, et al. Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro. Antimicrob Agents Chemother 2010; 54:3395-3401.
58. Borges S, Cravo P, Creasey A, et al. Genome-wide scan reveals amplification of mdr1 as a common denominator of resistance to mefloquine, lumefantrine and artemisinin in P. chabaudi malaria parasites. Antimicrob Agents Chemother 2011; 55:4858-4865.
59. Veiga MI, Ferreira PE, Jornhagen L, et al. Novel polymorphisms in Plasmodium falciparum ABC transporter genes are associated with major ACT antimalarial drug resistance. PLoS One 2011; 6:e20212.
60. Hunt P, Afonso A, Creasey A, et al. Gene encoding a deubiquitinating enzyme is mutated in artesunate- and chloroquine-resistant rodent malaria parasites. Mol Microbiol 2007; 65:27-40. (Pubitemid 46934481)
61. Imwong M, Dondorp AM, Nosten F, et al. Exploring the contribution of candidate genes to artemisinin resistance in Plasmodium falciparum. Antimicrob Agents Chemother 2010; 54:2886-2892.
62. Beez D, Sanchez CP, Stein WD, Lanzer M. Genetic predisposition favors the acquisition of stable artemisinin resistance in malaria parasites. Antimicrob Agents Chemother 2011; 55:50-55.
63. Yuan J, Cheng KC, Johnson RL, et al. Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. Science 2011; 333:724-729.
64. Hu G, Cabrera A, Kono M, et al. Transcriptional profiling of growth perturbations of the human malaria parasite Plasmodium falciparum. Nat Biotechnol 2010; 28:91-98.
65. Codd A, Teuscher F, Kyle DE, et al. Artemisinin-induced parasite dormancy: A plausible mechanism for treatment failure. Malar J 2011; 10:56.
66. Saralamba S, Pan-Ngum W, Maude RJ, et al. Intrahost modeling of artemisinin resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A 2010; 108:397-402.
67. The malERA Consultative Group on Drugs. A research agenda for malaria eradication: drugs. PLoS Med 2011; 8:e1000402.
68. The malERA Consultative Group on Diagnoses and Diagnostics. A research agenda for malaria eradication: diagnoses and diagnostics. PLoS Med 2011; 8:e1000396.
69. Tshefu AK, Gaye O, Kayentao K, et al. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemetherlumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: A randomised noninferiority trial. Lancet 2010; 375: 1457-1467.
70. Song J, Socheat D, Tan B, et al. Randomized trials of artemisinin-piperaquine, dihydroartemisinin-piperaquine phosphate and artemether-lumefantrine forthe treatment of multidrug resistant falciparum malaria in Cambodia-Thailand border area. Malar J 2011; 10:231.
71. Trape JF, Tall A, Diagne N, et al. Malaria morbidity and pyrethroid resistance after the introduction of insecticide-treated bednets and artemisinin-based combination therapies: A longitudinal study. Lancet Infect Dis (in press).
72. Laxminarayan R, Over M, Smith DL. Will a global subsidy of new antimalarials delay the emergence of resistance and save lives? Health Aff (Millwood) 2006; 25:325-336. (Pubitemid 43529540)
73. Adeyi O, Atun R. Universal access to malaria medicines: innovation in financing and delivery. Lancet 2010; 376:1869-1871.